Skip to Content

Rule

New Animal Drugs for Use in Animal Feed; Withdrawal of Approval of a New Animal Drug Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notification of withdrawal.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of eight new animal drug applications (NADAs) at the sponsor's request because these products are no longer manufactured or marketed.

DATES:

Withdrawal of approval is effective September 8, 2016.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Sujaya Dessai, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285 has requested that FDA withdraw approval of the NADAs listed in the following table because the products are no longer manufactured or marketed:

File No.Product name21 CFR section
012-548 1TYLOSIN (tylosin phosphate)/HYGROMIX (hygromycin B)558.274
013-162 1TYLAN TM (tylosin phosphate) Type A medicated article558.625
Start Printed Page 59136
013-388 1TYLAN (tylosin phosphate)/HYGROMIX (hygromycin B) Premix558.274
015-166 1TYLAN TM (tylosin phosphate) Type A medicated article558.625
127-507 1TYLAN 5 SULFA-G (tylosin phosphate and sulfamethazine), TYLAN 10 SULFA-G (tylosin phosphate and sulfamethazine), TYLAN 20 SULFA-G (tylosin phosphate and sulfamethazine), TYLAN 40 SULFA-G (tylosin phosphate and sulfamethazine)558.630
141-164 1TYLAN (tylosin phosphate)/COBAN (monensin)558.355
141-170 1TYLAN (tylosin phosphate)/MONTEBAN (narasin)558.363
141-198 1TYLAN TM (tylosin phosphate)/BIO-COX (salinomycin)558.550
1 These NADAs were identified as being affected by guidance for industry #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,” December 2013.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 012-548, 013-162, 013-388, 015-166, 127-507, 141-164, 141-170, and 141-198, and all supplements and amendments thereto, is hereby withdrawn, effective September 8, 2016.

Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Start Signature

Dated: August 8, 2016.

Tracey H. Forfa,

Deputy Director, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 2016-19915 Filed 8-26-16; 8:45 am]

BILLING CODE 4164-01-P